US · MDGL · BIOTECHNOLOGY
Madrigal Pharmaceuticals, Inc. (MDGL) intrinsic value and stock valuation
$379.10as of 2026-11-21 · Mkt cap 11.88B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Madrigal Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values MDGL with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from MDGL’s statements →
Madrigal Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Moderna, Inc. (MRNA) $195.00
- Jazz Pharmaceuticals plc (JAZZ) $230.26
- Exelixis, Inc. (EXEL) $64.63
- Baxter International Inc. (BAX) $25.39
- BioMarin Pharmaceutical Inc. (BMRN) $60.41
- Bio-Techne Corporation (TECH) $72.67
- Abivax S.A. (ABVX) $73.20
- Rhythm Pharmaceuticals, Inc. (RYTM) $112.36
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $958.4M | $180.1M | $0.00 | $0.00 | $0.00 |
| Operating income | -$-300.1M | -$-497.88M | -$-380.5M | -$-293.57M | -$-242.48M |
| Net income | -$-288.28M | -$-465.89M | -$-373.63M | -$-295.35M | -$-241.85M |
| EPSd | -$-12.85M | -$-21.9M | -$-19.99M | -$-17.23M | -$-14.62M |
| Operating cash flow | -$-189.55M | -$-455.57M | -$-324.23M | -$-224.86M | -$-183.92M |
| Capital expenditure | -$-470K | -$-1.46M | -$-1.48M | -$-220K | -$-210K |
| Free cash flow | -$-190.02M | -$-457.03M | -$-325.71M | -$-225.07M | -$-184.13M |
| Total assets | $1.26B | $1.04B | $640.6M | $362.6M | $273.3M |
| Total debt | $354.4M | $119.6M | $117.2M | $49.9M | $800K |
| Net debt | $155.7M | $19.6M | $17.3M | -$-281.66M | -$-35.47M |
| Total equity | $602.7M | $754.4M | $405.3M | $197.4M | $196.1M |
| Cash and short-term investments | $983.6M | $926.3M | $634.1M | $358.8M | $270.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $958.4M | $180.1M | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $56.2M | $6.23M | $0.00 | $0.00 | $0.00 |
| Gross profit | $902.3M | $173.9M | $0.00 | $0.00 | $0.00 |
| Research and development expenses | $388.5M | $236.7M | $272.4M | $245.4M | $205.2M |
| Selling, general and administrative expenses | $813.8M | $435.1M | $108.2M | $48.1M | $37.3M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $1.2B | $671.8M | $380.5M | $293.6M | $242.5M |
| Cost and expenses | $1.26B | $678M | $380.5M | $293.6M | $242.5M |
| Interest income | $37.4M | $46.7M | $19.6M | $2.19M | $360K |
| Interest expense | $22.3M | $14.7M | $12.7M | $3.96M | $0.00 |
| Depreciation and amortization | $1.51M | $1.1M | $530K | $470K | $410K |
| Ebitda | -$-264.47M | -$-450.12M | -$-360.39M | -$-290.92M | -$-241.44M |
| Operating income | -$-300.1M | -$-497.88M | -$-380.5M | -$-293.57M | -$-242.48M |
| Total other income/expenses, net | $11.8M | $32M | $6.87M | -$-1.78M | $640K |
| Income before tax | -$-288.28M | -$-465.89M | -$-373.63M | -$-295.35M | -$-241.85M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-288.28M | -$-465.89M | -$-373.63M | -$-295.35M | -$-241.85M |
| Weighted average shares outstanding | $22.4M | $21.3M | $18.7M | $17.1M | $16.5M |
| Weighted average diluted shares outstanding | $22.4M | $21.3M | $18.7M | $17.1M | $16.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $983.6M | $926.3M | $634.1M | $358.8M | $270.4M |
| Net receivables | $134.5M | $53.8M | $0.00 | $0.00 | $0.00 |
| Inventory | $74.8M | $34.1M | $0.00 | $0.00 | $0.00 |
| Total current assets | $1.25B | $1.03B | $637.3M | $361.4M | $271.7M |
| Property, plant and equipment, net | $6.44M | $4.59M | $3.27M | $1.2M | $1.65M |
| Goodwill and intangible assets | $7.38M | $4.73M | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $13.8M | $9.32M | $3.27M | $1.2M | $1.65M |
| Total assets | $1.26B | $1.04B | $640.6M | $362.6M | $273.3M |
| Accounts payable | $48.9M | $43.6M | $28M | $23.8M | $21.4M |
| Short-term debt | $1.02M | $980K | $530K | $600K | $410K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $310.3M | $169.3M | $118.6M | $115.9M | $76.8M |
| Long-term debt | $353.3M | $118.6M | $116.7M | $49.3M | $390K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $346.6M | $118.6M | $116.7M | $49.3M | $390K |
| Capital lease obligations | $6.73M | $2M | $1.71M | $600K | $800K |
| Total liabilities | $656.9M | $287.9M | $235.2M | $165.2M | $77.2M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-2.09B | -$-1.8B | -$-1.34B | -$-962.66M | -$-667.31M |
| Accumulated other comprehensive income (loss) | $870K | $470K | $470K | -$-30K | -$-80K |
| Total equity | $602.7M | $754.4M | $405.3M | $197.4M | $196.1M |
| Total investments | $784.9M | $826.2M | $534.2M | $27.2M | $234.1M |
| Total debt | $354.4M | $119.6M | $117.2M | $49.9M | $800K |
| Net debt | $155.7M | $19.6M | $17.3M | -$-281.66M | -$-35.47M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-288.28M | -$-465.89M | -$-373.63M | -$-295.35M | -$-241.85M |
| Depreciation and amortization | $4.72M | $700K | $530K | $470K | $410K |
| Stock-based compensation | $98.1M | $79.9M | $49.7M | $31.6M | $26.9M |
| Change in working capital | -$-8.5M | -$-72.34M | -$-3.28M | $37.6M | $30.7M |
| Accounts receivable | -$-80.65M | -$-53.82M | $0.00 | $0.00 | $0.00 |
| Inventory | -$-36.98M | -$-34.07M | $0.00 | $0.00 | $0.00 |
| Accounts payable | $5.28M | $15.6M | $4.21M | $2.45M | $20.4M |
| Net cash provided by operating activities | -$-189.55M | -$-455.57M | -$-324.23M | -$-224.86M | -$-183.92M |
| Investments in property, plant and equipment | -$-470K | -$-1.46M | -$-1.48M | -$-220K | -$-210K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$0.00 | $790K |
| Net cash used for investing activities | $32.3M | -$-274.39M | -$-502.52M | $206.7M | -$-5.05M |
| Common stock issued | $38.1M | $397.5M | $260.2M | $255.4M | $170.2M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $256M | $735.1M | $595.1M | $313.5M | $171.2M |
| Net change in cash | $98.8M | $5.1M | -$-231.63M | $295.3M | -$-17.73M |
| Cash at end of period | $203.8M | $105M | $99.9M | $331.6M | $36.3M |
| Operating cash flow | -$-189.55M | -$-455.57M | -$-324.23M | -$-224.86M | -$-183.92M |
| Capital expenditure | -$-470K | -$-1.46M | -$-1.48M | -$-220K | -$-210K |
| Free cash flow | -$-190.02M | -$-457.03M | -$-325.71M | -$-225.07M | -$-184.13M |
Line items
Line items
Line items
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
- CEO
- William J. Sibold
- Employees
- 915
- Beta
- -1.06
Explore
Frequently asked questions
What is the intrinsic value of Madrigal Pharmaceuticals, Inc. (MDGL)?
Madrigal Pharmaceuticals, Inc. (MDGL) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is MDGL undervalued?
MDGL trades at a price of $379.10 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.